News Archive

GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.

NEW YORK – Qiagen said on Tuesday that it has received a CE-IVD mark for its Artus SARS-CoV-2 Prep&Amp UM Kit for high-throughput PCR-based COVID-19 testing.

The kit is now commercially available in the EU and other markets accepting the CE-IVD mark, and Qiagen has submitted an Emergency Use Authorization application for the assay to the US Food and Drug Administration.

The Quantum Startup Foundry (QSF) at the University of Maryland brings together the resources needed—physical and virtual—to support entrepreneurs and startups in accelerating quantum technologies’ time to market. QSF will bring entrepreneurs together with industry and government customers, investors, technical mentors, leading-edge research and IP, and quantum-specific infrastructure (equipment, tools, facilities). Located in the Washington, DC metro area, QSF offers the perfect landing and launch spot for quantum companies.

A group of top lawmakers of both parties in both chambers of Congress on Wednesday reintroduced legislation that aims to spend $110 billion on vital technologies to sustain American leadership and spur competitiveness against China.

The draft bill, known as the Endless Frontier Act, championed by Senate Majority Leader Charles E. Schumer, D-N.Y., and Sen. Todd Young, R-Ind., is matched by a companion bill in the House by Reps. Ro Khanna, D-Calif., and Mike Gallagher, R-Wis.

The Matan Cos. will add biotech manufacturing and research space to one of its existing office campuses in Germantown to meet the surge in demand from local life sciences firms.

The new construction is slated for the Milestone Business Park, located just off Interstate 270 at the Father Hurley Boulevard exit, the Frederick-based developer told the Washington Business Journal. Matan plans to add three new buildings totaling 532,000 square feet, constructing them on some of the site’s ample parking lots and rebranding the campus as “Milestone Innovation Park.”

Image: Matan Cos. plans to add three new biotech-focused manufacturing and research buildings at its Milestone office park in Germantown. HIGH ROCK STUDIOS

With its unique system of intramural and extramural research programs, funding for academic and corporate product development, along with its supporting foundations, the National Institutes of Health (NIH) has created a vibrant public “innovation ecosystem” that has changed not only the face of healthcare, but has also led to the creation of the biotech industry in the U.S. Whether your interest in the overall healthcare environment is scientific, medical, educational or commercial, there is something here for you.

Image: Dr Joseph J.Kinyoun, NIH Founder – https://www.ncbi.nlm.nih.gov

ROCKVILLE, Md., April 19, 2021 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Rhonda Henry has joined the company as President of Emmes BioPharma.

“Naming a leader of our biopharma group is a major, positive step in our strategy to expand and diversify our business,” said Dr. Christine Dingivan, Chief Executive Officer of Emmes.